Insulin glargine biosimilar(Shandong New Time Pharmaceutical)

重组甘精胰岛素生物类似药（山东新时代药业）

Report date: 2022/05/16 09:20:55

Base Information

Drug NameInsulin glargine biosimilar(Shandong New Time Pharmaceutical)
Drug Alias Name甘精胰岛素生物仿制药（山东新时代药业）insulin glargine follow-on biologic重组甘精胰岛素生物仿制药（山东新时代药业）
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsDiabetes Mellitus
Approved Indications in ChinaDiabetes Mellitus
Original Approved Country/TerritoryMainland China
Original Approved Date2022/05/10
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesLunan Pharmaceutical Group Co
China Registration ClassN/A

Develop Information

Active CompaniesShandong New Time Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeA10AE04
Related LinksN/A